Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC)
2024-511053-22-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Simvastatin with Placebo (2 arms). Primary endpoints: Number of days from randomisation to death, Number of days from randomisation to listing of liver transplantation and 2 more. Planned start May 2020; status: authorised.
02
Drugs
simvastatin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2024-511053-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511053-22-00.